Journal
MOLECULAR THERAPY
Volume 17, Issue 7, Pages 1125-1135Publisher
CELL PRESS
DOI: 10.1038/mt.2009.73
Keywords
-
Categories
Funding
- Dixon Fellowship
- Pediatric Brain Tumor Foundation
- USPHS NCI [P01 CA071933, P50 CA097247]
Ask authors/readers for more resources
Despite improving survival rates for children with cancer, a subset of patients exist with disease resistant to traditional therapies such as surgery, chemotherapy, and radiation. These patients require newer, targeted treatments used alone or in combination with more traditional approaches. Oncolytic herpes simplex virus (HSV) is one of these newer therapies that offer promise for several difficult to treat pediatric malignancies. The potential benefit of HSV therapy in pediatric solid tumors including brain tumors, neuroblastomas, and sarcomas is reviewed along with the many challenges that need to be addressed prior to moving oncolytic HSV therapy from the laboratory to the beside in the pediatric population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available